Comparison
Ipamorelin vs Sermorelin: Research Comparison
A ghrelin-receptor GHRP set beside a GHRH analog — two different mechanisms, two different evidence bases, often paired rather than chosen between.
The short version
Ipamorelin vs sermorelin is, at heart, a comparison of two different keys to the same lock. Both raise growth hormone, but by different receptors. Ipamorelin is a GHRP — it works on the ghrelin receptor (GHS-R1a) and delivers a clean, selective GH pulse. Sermorelin is a GHRH analog — it mimics the body's own growth-hormone-releasing hormone and works on the GHRH receptor. Because the two mechanisms are complementary, they are more often combined than chosen between, the same way ipamorelin is paired with the longer-acting GHRH analog CJC-1295. The biggest practical contrast is regulatory history, not pharmacology: sermorelin has an approved-drug past, while ipamorelin has never been approved anywhere and failed its only human efficacy trial. This page compares mechanism, duration, and evidence, with every figure cited.
Mechanism — different receptors, complementary actions
Ipamorelin activates the ghrelin / GHS-R1a receptor on pituitary somatotrophs to release GH, and its defining trait is selectivity — no meaningful rise in ACTH, cortisol, or prolactin [1]. Sermorelin acts on the GHRH receptor, the same receptor the body's own GHRH uses. The two are not substitutes at the molecular level: a GHRP and a GHRH analog stimulate GH through distinct, synergistic pathways, which is the whole basis for combining the classes [7]. A neuroendocrine review describes the circuit-level cooperation — ghrelin-receptor agonists suppress somatostatin and amplify GHRH signaling at the pituitary [9]. So ipamorelin vs sermorelin is less a rivalry than a description of two complementary tools.
Duration and pharmacokinetics
Ipamorelin's terminal half-life in people is about 2 hours, and it produces a single GH pulse peaking near 40 minutes after dosing [2]. Sermorelin is also short-acting — both ipamorelin and sermorelin are short-duration agents compared with the long-acting GHRH analog CJC-1295, which sustained 2- to 10-fold GH elevation for more than six days after a single dose in healthy adults [11]. That contrast in duration is exactly why community protocols tend to pair a short GHRP like ipamorelin with a longer-acting GHRH analog rather than with a short one — to combine an acute pulse with a sustained elevation. Note that the CJC-1295 figures come from a study on CJC-1295, not on ipamorelin or sermorelin [11].
Evidence and regulatory status
The sharpest difference between the two is the evidence and approval history. Ipamorelin has never been approved as a drug anywhere; its only Phase 2 trial, for postoperative ileus, missed its primary endpoint, and it was reviewed by the FDA's Pharmacy Compounding Advisory Committee in 2024 and removed from the interim 503A Category 2 bulk-substances list [3]. Sermorelin, by contrast, has an approved-drug history as a GHRH analog. Both are prohibited in sport under WADA category S2 as growth hormone secretagogues [12]. For a research reader, the takeaway is that "ipamorelin vs sermorelin" compares a never-approved selective GHRP against a GHRH analog with a regulatory track record — different classes, different evidentiary footing.
Can they be combined
Yes, in principle the classes are combinable — a GHRP and a GHRH analog act synergistically, which is the documented rationale for any GHRH+GHRP pairing [7] [9]. In practice, community stacks more often pair ipamorelin with the long-acting GHRH analog CJC-1295 than with the short-acting sermorelin, to get a sustained GHRH-driven elevation alongside the ipamorelin pulse [11]. But the same caveat that governs the ipamorelin cjc-1295 stack applies here: no controlled trial has tested any ipamorelin-plus-GHRH-analog combination for an outcome. The synergy is read off single-agent pharmacology, and combination-specific safety and efficacy in humans remain uncharacterized [3].